Analysis of the real situation of medication in the population with gout achieving T2T indicators: a multicentre real-world study
10.3760/cma.j.cn141217-20221026-00444
- VernacularTitle:痛风达标治疗人群用药真实情况分析：多中心真实世界研究结果
- Author:
Weiqin GAO
1
;
Xuezhong GONG
;
Yuanyuan ZHANG
;
Xingchen DU
;
Ping JIANG
;
Fengyuan GUAN
;
Ying LU
;
Xiao SU
;
Hongze JIANG
;
Hongbin LI
;
Yongfei FANG
;
Hengli ZHAO
;
Jiangyun PENG
;
Mingli GAO
;
Li SU
;
Fang HE
;
Qingwen TAO
;
Chunrong HU
;
Peng LI
;
Zeguang LI
;
Yuelan ZHU
;
Ying GU
;
Ming ZHANG
;
Rongsheng WANG
;
Ting JIANG
;
Xiaolin YANG
;
Qi ZHU
;
Quan JIANG
;
Jianyong ZHANG
;
Xiaolei FAN
;
Yu XUE
;
Dongyi HE
Author Information
1. 上海中医药大学附属光华中西医结合医院风湿免疫科，上海 200052
- Keywords:
Gout;
Uric acid;
Treat-to-target;
Real-world
- From:
Chinese Journal of Rheumatology
2023;27(6):361-367
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the therapeutic characteristics of population with gout achieving treat-to-target (T2T) indicators through real-world research and evaluate their safety.Methods:A total of 3 287 patients diagnosed with gout by rheumatologists in 21 first-class tertiary hospitals in 10 provinces, municipalities, and autonomous regions in China from January 2015 to December 2021 were included in this polycentric cross-sectional study. The database included patients′ general information, disease characteristics, and clinical application of traditional Chinese and Western medicine treatment measures. SPSS and Excel software were used for data analysis. Frequency analysis, cluster analysis, and factor analysis were used to summarize the characteristics and rules of treatment measures for patients with gout who achieved the target after treatment. The occurrence of adverse events (AE) was recorded during treatment.Results:After treatment, 691 visits (7%) achieved the serum urate (SUA) target, and the most frequent use of urate-lowering therapy (ULT) was febuxostat, followed by benzbromarone. The most common treatment options were following: GroupⅠ: traditional Chinese medicine (TCM) decoction-TCM external treatment-physical exercise-proprietary Chinese medicine; GroupⅡ: ferulic acid-nonsteroidal anti-inflammatory drugs (NSAIDs); Group Ⅲ: allopurinol-sodium bicarbonate-benzbromarone; Group Ⅳ: glucocorticoid-colchicine; Group Ⅴ: febuxostat. A total of 5 898 visits (60%) chieved manifestations of joint pain VAS scores target, and the most frequently used drug to control joint symptoms was NSAIDs. The frequency of use of drugs to control joint symptoms were 2 118 times (usage rate reached 35.9%), while the frequency of ULT were 2 504 times (usage rate reached 42.5%), which was higher than the joint symptom control drug. The most common treatment options were following: Group Ⅰ: proprietary Chinese medicine-TCM decoction-TCM external treatment-physical exercise; Group Ⅱ: NSAIDs-colchicine hormones; Group Ⅲ: allopurinol, Group Ⅳ: benzbromarone; Group Ⅴ: febuxostat. A total of 59 adverse events occurred during treatment.Conclusion:The proportions of gout patients who reach target serum urate level & good control of joint symptoms are both very low, and ULT and anti-inflammatory prescription patterns are very different from international guidelines, so it is necessary to strengthen the standardized management of gout patients. At the same time, life intervention measures account for a certain proportion of the treatment plans for the T2T population, and further exploration is needed.
